Axonics Modulation Technologies has received the US Food and Drug Administration (FDA) approval for 3T full-body magnetic resonance imaging (MRI) conditional labelling for its r-SNM System under a premarket approval (PMA) supplement.

With the new approval, the device is the sacral neuromodulation (SNM) System available in the US with MRI compatibility for both 1.5T and 3T full-body scans.

The company acquired the regulatory approval for r-SNM System to treat faecal incontinence last year. It also received the European CE-Mark approval for MRI conditional labelling of the r-SNM System.

Axonics CEO Raymond Cohen said: “This FDA approval allows Axonics to provide healthcare professionals with more choices in selecting the optimal MR scanner for their patients’ imaging needs.

“We expect SNM to become the preferred therapy for patients suffering from overactive bladder and bowel dysfunction and we remain confident that our keen focus on innovation and increasing patient awareness will significantly expand the SNM market in the years ahead.”

Last month, Axonics was granted FDA approval for its SmartMRI wireless patient Remote Control for the r-SNM System.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Axonics focuses on developing implantable SNM devices for the treatment of urinary and bowel dysfunction.

These conditions significantly impact the quality of life and result from miscommunication between the bladder and the brain.

Almost 87 million adults in the US and Europe are estimated to suffer from overactive bladder. Faecal incontinence / accidental bowel leakage affects another estimated 40 million adults.